Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer☆

[1]  E. Kikuchi,et al.  Potent increased risk of the initiation of DNA replication in human prostate cancer with the use of 5α-reductase inhibitors. , 2014, American journal of clinical and experimental urology.

[2]  Ian M Thompson,et al.  Long-term survival of participants in the prostate cancer prevention trial. , 2013, The New England journal of medicine.

[3]  C. Logothetis,et al.  Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. , 2013, Cancer discovery.

[4]  H. Parnes,et al.  Prostate cancer prevention: strategies for agent development , 2013, Current opinion in oncology.

[5]  P. Troncoso,et al.  Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers , 2013, The Prostate.

[6]  M. Lucia,et al.  Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial , 2012, The Lancet.

[7]  D. Tsavachidou,et al.  Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Mills,et al.  Androgen Regulation of 5α-Reductase Isoenzymes in Prostate Cancer: Implications for Prostate Cancer Prevention , 2011, PloS one.

[9]  P. Nelson,et al.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. , 2011, Cancer cell.

[10]  I. Leav,et al.  ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. , 2010, Cancer cell.

[11]  D. Tindall,et al.  Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.

[12]  R. Ummanni,et al.  Immunohistochemical expression of caspase-1 and -9, uncleaved caspase-3 and -6, cleaved caspase-3 and -6 as well as Bcl-2 in benign epithelium and cancer of the prostate. , 2010, Experimental and therapeutic medicine.

[13]  M. Shen,et al.  A luminal epithelial stem cell that is a cell of origin for prostate cancer , 2009, Nature.

[14]  J. Thrasher,et al.  Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. , 2009, The Journal of urology.

[15]  豊 木村,et al.  胃癌手術におけるCommon Terminology Criteria for Adverse Events v3.0を利用した合併症の評価 , 2009 .

[16]  K. Leong,et al.  Generation of a prostate from a single adult stem cell , 2008, Nature.

[17]  C. K. Too,et al.  Levels of 5α-Reductase Type 1 and Type 2 are Increased in Localized High Grade Compared to Low Grade Prostate Cancer , 2008 .

[18]  C. K. Too,et al.  Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. , 2008, The Journal of urology.

[19]  M. Kattan,et al.  Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. , 2007, Journal of the National Cancer Institute.

[20]  D. Bostwick,et al.  The effects of the dual 5α‐reductase inhibitor dutasteride on localized prostate cancer—results from a 4‐month pre‐radical prostatectomy study , 2006, The Prostate.

[21]  Ximing J. Yang,et al.  Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer , 2006, BMC Cancer.

[22]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[23]  D. Troyer,et al.  Differential alterations in 5α‐reductase type 1 and type 2 levels during development and progression of prostate cancer , 2005 .

[24]  D. Troyer,et al.  Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. , 2005, The Prostate.

[25]  M. Gleave,et al.  Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. , 2004, The Journal of urology.

[26]  W. Gerald,et al.  Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. , 2004, Endocrine-related cancer.

[27]  Michael M Lieber,et al.  Journal Review , 2003, International Society of Hair Restoration Surgery.

[28]  R. Lathe,et al.  An endocrine pathway in the prostate, ERβ, AR, 5α-androstane-3β,17β-diol, and CYP7B1, regulates prostate growth , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Lathe,et al.  An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.